Australia's Neuren Pharma at more than 2-month-low on revising royalty outlook

Neuren Pharmaceuticals

06/11/2025 01:23

** Neuren Pharmaceuticals NEU.AX slips as much as 11.3% to A$17.95, lowest since August 27; among top losers on S&P/ASX 200 index .AXJO

** Biopharma co says Nasdaq-listed Acadia AACD.O narrowed FY25 U.S. net sales outlook for co's Rett syndrome medication, DAYBUE, to $385 mln–400 mln from $380 mln-405 mln

** Neuren granted exclusive worldwide licence to Acadia for development, commercialisation of DAYBUE

** Outlook revision implies FY25 U.S. royalty income for Neuren seen at A$63 mln ($41 mln)-A$66 mln vs A$62 mln-A$67 mln expected earlier

** YTD, NEU gains 49.8%

($1 = A$1.5389)

 (Reporting by Shruti Agarwal in Bengaluru)

 ((Shruti.Agarwal@thomsonreuters.com))